Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VIOLETTE F HENEIN

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1912914227
CMS profile
41158
Location
CLINTON TOWNSHIP, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,885.17

154 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,754.76 152
Education $130.41 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VIOLETTE F HENEIN

NPI 1912914227 · CMS profile ID 41158

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

CLINTON TOWNSHIP, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1912914227?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VIOLETTE F HENEIN, NPI 1912914227, CMS profile ID 41158. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912914227?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). VIOLETTE F HENEIN, NPI 1912914227, CMS profile ID 41158. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912914227?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
VIOLETTE F HENEIN, NPI 1912914227, CMS profile ID 41158, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1912914227?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

154 matching records · $2,885.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 154 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 154.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $9.0405/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021486665 CMS
Amgen Inc. $24.6805/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020190077 CMS
Amgen Inc. $25.7305/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020190097 CMS
Horizon Therapeutics plc $23.6505/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987018675 CMS
UCB, Inc. $2.0005/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021486613 CMS
UCB, Inc. $2.1705/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021486615 CMS
UCB, Inc. $7.7105/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021486629 CMS
UCB, Inc. $8.0905/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021486641 CMS
Amgen Inc. $27.5005/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020695319 CMS
Lilly USA, LLC $18.6004/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032423603 CMS
PFIZER INC. $22.0204/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050662095 CMS
ABBVIE INC. $18.4204/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997464669 CMS
Fresenius Kabi USA, LLC $29.5304/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060084967 CMS
Horizon Therapeutics plc $4.7004/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987018671 CMS
Organon LLC $19.5104/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046928099 CMS
UCB, Inc. $8.6404/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021486657 CMS
ABBVIE INC. $25.5004/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997464667 CMS
Horizon Therapeutics plc $8.2004/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987018667 CMS
Mylan Institutional Inc. $17.2804/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039005035 CMS
Amgen Inc. $20.0104/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020190053 CMS
Novartis Pharmaceuticals Corporation $21.5403/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992235055 CMS
Amgen Inc. $22.2103/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020190093 CMS
ABBVIE INC. $2.4503/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997464665 CMS
PFIZER INC. $1.6603/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050655439 CMS
PFIZER INC. $24.1803/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050658777 CMS
Janssen Biotech, Inc. $15.7403/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988417001 CMS
Amgen Inc. $27.3403/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020695317 CMS
GlaxoSmithKline, LLC. $21.6803/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000971179 CMS
AstraZeneca Pharmaceuticals LP $23.2303/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015363017 CMS
Amgen Inc. $22.9603/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020190069 CMS
Lilly USA, LLC $21.3703/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032660925 CMS
Amgen Inc. $6.2703/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020190073 CMS
Ferring Pharmaceuticals Inc. $16.3303/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044164845 CMS
Horizon Therapeutics plc $20.6203/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987018663 CMS
Aurinia Pharma U.S., Inc. $16.7503/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735081 CMS
Janssen Biotech, Inc. $28.3303/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988416983 CMS
Radius Health, Inc. $22.5103/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024719573 CMS
AstraZeneca Pharmaceuticals LP $13.3502/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011270935 CMS
UCB, Inc. $7.0502/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021486621 CMS
PFIZER INC. $15.0402/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050655437 CMS
Amgen Inc. $28.9502/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020190089 CMS
Novartis Pharmaceuticals Corporation $25.0602/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992235051 CMS
ABBVIE INC. $30.6902/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997464663 CMS
Organon LLC $17.3202/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046928077 CMS
Amgen Inc. $10.4402/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020190105 CMS
Horizon Therapeutics plc $8.1202/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987018655 CMS
Horizon Therapeutics plc $26.0002/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987018659 CMS
Amgen Inc. $8.1502/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020190049 CMS
Novartis Pharmaceuticals Corporation $4.0801/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992235035 CMS
GlaxoSmithKline, LLC. $22.9501/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000969326 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $73.17 4
PY2020 $114.95 6
PY2021 $52.98 3
PY2022 $1,219.46 65
PY2023 $2,885.17 154
PY2024 $2,645.38 145
PY2025 $2,917.18 141

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2020 Recipient $3,559.87 10
PY2020 Principal investigator $11,250.00 1
PY2019 Recipient $762.84 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

11 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Eli Lilly and Company $1,629.79 04/08/2020 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 728725468
Principal investigator 1 Gilead Sciences, Inc. $11,250.00 02/24/2020 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN, LLC
A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in subjects with Active Psoriatic Arthritis Who Are Naive to Biological DMARD Therapy. No dispute reported 06/30/2026 742090039
Recipient Gilead Sciences, Inc. $41.09 01/30/2020 Covered Recipient Physician A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in subjects with Active Psoriatic Arthritis Who Are Naive to Biological DMARD Therapy. No dispute reported 06/30/2026 742085511
Recipient Gilead Sciences, Inc. $50.00 01/30/2020 Covered Recipient Physician A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in subjects with Active Psoriatic Arthritis Who Are Naive to Biological DMARD Therapy. No dispute reported 06/30/2026 742085513
Recipient Gilead Sciences, Inc. $50.00 01/30/2020 Covered Recipient Physician A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in subjects with Active Psoriatic Arthritis Who Are Naive to Biological DMARD Therapy. No dispute reported 06/30/2026 742085515
Recipient Gilead Sciences, Inc. $75.00 01/30/2020 Covered Recipient Physician A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in subjects with Active Psoriatic Arthritis Who Are Naive to Biological DMARD Therapy. No dispute reported 06/30/2026 742085517
Recipient Gilead Sciences, Inc. $82.50 01/30/2020 Covered Recipient Physician A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in subjects with Active Psoriatic Arthritis Who Are Naive to Biological DMARD Therapy. No dispute reported 06/30/2026 742085519
Recipient Gilead Sciences, Inc. $125.00 01/30/2020 Covered Recipient Physician A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in subjects with Active Psoriatic Arthritis Who Are Naive to Biological DMARD Therapy. No dispute reported 06/30/2026 742085521
Recipient Gilead Sciences, Inc. $125.07 01/30/2020 Covered Recipient Physician A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in subjects with Active Psoriatic Arthritis Who Are Naive to Biological DMARD Therapy. No dispute reported 06/30/2026 742085523
Recipient Gilead Sciences, Inc. $556.62 01/30/2020 Covered Recipient Physician A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in subjects with Active Psoriatic Arthritis Who Are Naive to Biological DMARD Therapy. No dispute reported 06/30/2026 742085525
Recipient Gilead Sciences, Inc. $824.80 01/30/2020 Covered Recipient Physician A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in subjects with Active Psoriatic Arthritis Who Are Naive to Biological DMARD Therapy. No dispute reported 06/30/2026 742085527